CHELSEA SMITH: Open Payments
NPI 1417443672 · BOSSIER CITY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$564 in 33 payments from 10 companies in 2025. Trend: 2023 $493 · 2024 $454 · 2025 $564
Food & beverage: $564
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $214 |
| ABBVIE INC. | 16 | $151 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $60 |
| Ethicon US, LLC | 1 | $31 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Novo Nordisk Inc | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| Corium, LLC | 1 | $13 |
Products named: AIRSUPRA, UBRELVY, CAPLYTA, QULIPTA, ETHICON, FANAPT, BREZTRI, REXULTI.
Industry payments across LA — which companies pay providers there.
